...
首页> 外文期刊>Toxicology and Applied Pharmacology >Contribution of acetaminophen-cysteine to acetaminophen nephrotoxicity in CD-1 mice: I. Enhancement of acetaminophen nephrotoxicity by acetaminophen-cysteine.
【24h】

Contribution of acetaminophen-cysteine to acetaminophen nephrotoxicity in CD-1 mice: I. Enhancement of acetaminophen nephrotoxicity by acetaminophen-cysteine.

机译:对乙酰氨基酚半胱氨酸对CD-1小鼠对乙酰氨基酚肾毒性的作用:I.对乙酰氨基酚半胱氨酸增强对乙酰氨基酚肾毒性。

获取原文
获取原文并翻译 | 示例
           

摘要

Acetaminophen (APAP) nephrotoxicity has been observed both in humans and research animals. Recent studies suggest a contributory role for glutathione (GSH)-derived conjugates of APAP in the development of nephrotoxicity. Inhibitors of either gamma-glutamyl transpeptidase (gamma-GT) or the probenecid-sensitive organic anion transporter ameliorate APAP-induced nephrotoxicity but not hepatotoxicity in mice and inhibition of gamma-GT similarly protected rats from APAP nephrotoxicity. Protection against APAP nephrotoxicity by disruption of these GSH conjugate transport and metabolism pathways suggests that GSH conjugates are involved. APAP-induced renal injury may involve the acetaminophen-glutathione (APAP-GSH) conjugate or a metabolite derived from APAP-GSH. Acetaminophen-cysteine (APAP-CYS) is a likely candidate for involvement in APAP nephrotoxicity because it is both a product of the gamma-GT pathway and a probable substrate for the organic anion transporter. The present experiments demonstrated that APAP-CYS treatment alone depleted renal but not hepatic glutathione (GSH) in a dose-responsive manner. This depletion of renal GSH may predispose the kidney to APAP nephrotoxicity by diminishing GSH-mediated detoxification mechanisms. Indeed, pretreatment of male CD-1 mice with APAP-CYS before challenge with a threshold toxic dose of APAP resulted in significant enhancement of APAP-induced nephrotoxicity. This was evidenced by histopathology and plasma blood urea nitrogen (BUN) levels at 24 h after APAP challenge. APAP alone was minimally nephrotoxic and APAP-CYS alone produced no detectable injury. By contrast, APAP-CYS pretreatment did not alter the liver injury induced by APAP challenge. These data are consistent with there being a selective, contributory role for APAP-GSH-derived metabolites in APAP-induced renal injury that may involve renal-selective GSH depletion.
机译:对乙酰氨基酚(APAP)的肾毒性已在人类和研究动物中观察到。最近的研究表明,谷胱甘肽(GSH)衍生的APAP缀合物在肾毒性的发展中起重要作用。 γ-谷氨酰转肽酶(γ-GT)或丙磺舒敏感的有机阴离子转运蛋白的抑制剂可改善APAP诱导的小鼠肾毒性,但不能改善肝毒性,并且对γ-GT的抑制同样可保护大鼠免受APAP肾毒性。通过破坏这些GSH缀合物的运输和代谢途径来保护免受APAP肾毒性提示,涉及GSH缀合物。 APAP诱发的肾损伤可能涉及对乙酰氨基酚-谷胱甘肽(APAP-GSH)结合物或源自APAP-GSH的代谢物。对乙酰氨基酚-半胱氨酸(APAP-CYS)可能是参与APAP肾毒性的候选药物,因为它既是γ-GT途径的产物,又是有机阴离子转运蛋白的可能底物。本实验表明,APAP-CYS单独以剂量反应方式消耗肾脏,但不消耗肝谷胱甘肽(GSH)。肾脏GSH的这种消耗可通过减少GSH介导的排毒机制使肾脏易患APAP肾毒性。实际上,在用阈值毒性剂量的APAP攻击前用APAP-CYS对雄性CD-1小鼠进行预处理可显着增强APAP诱导的肾毒性。 APAP激发后24小时的组织病理学和血浆血尿素氮(BUN)水平证明了这一点。单独的APAP具有最小的肾毒性,单独的APAP-CYS不会产生可检测的损伤。相比之下,APAP-CYS预处理并未改变APAP激发所致的肝损伤。这些数据与APAP-GSH衍生的代谢产物在APAP诱发的肾损伤中可能具有肾脏选择性GSH耗竭的作用有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号